TX-MAVENIR
5.2.2018 14:02:13 CET | Business Wire | Press release
Mavenir , focused on transforming mobile network economics for Communications Service Providers (CSPs), today announced it has acquired Argyle Data , the first big data and machine learning security platform that delivers real-time anomaly detection and predictive analytics for mobile service providers and IoT networks. Engineered for the most challenging mobile environments, its supervised and unsupervised Machine Learning algorithms enable superior network traffic insights and comprehensive fraud detection on mobile voice and data planes.
Machine learning analytics is increasingly viewed as a key tool to improve the efficiency and profitability of mobile carrier networks1 . With the introduction of 5G technology and the growth in new communication patterns, applications and devices, new vulnerabilities are being exposed.
As more and more IoT devices are connected, the threat vector will widen, placing more devices at risk of hacking, and more users at risk of having their personal data accessed, or falling victim to fraud2 . The number of connected Internet of Things (IoT) devices worldwide will jump from nearly 27 billion in 2017 to 125 billion in 20303 .
Rules-based and batch processing systems are insufficient. CSPs now require a modern, scalable approach to fight fraud, negative margins and arbitrage activity in real-time with supervised and unsupervised machine learning. An adaptive big data analytics approach is ideally suited to manage the volume, velocity and variety of structured and unstructured data over wireless networks.
Argyle Data technology can analyze terabytes of various data streams and protocols per second in real time with machine learning analytics that enable operators to reduce fraud and offer differentiated services because of their data insights.
“Unlike mobile devices like phones and tablets, IoT have little or no built in protection as security has not been a top priority in development, yet they are connected to mobile networks,” said Pardeep Kohli, President and CEO of Mavenir. “The addition of the Argyle team and its platform enhances Mavenir’s existing 5G, security and signaling machine learning suite to offer next generation revenue protection for mobile network operators and their subscribers.”
Added Kohli, “Only machine learning algorithms built to enable artificial intelligence systems are capable with these growing numbers of devices, to detect zero-day vulnerabilities in mobile networks, preventing increased financial risks.”
Mavenir’s cloud-native Security Suite includes Messaging Spam and Fraud control, Equipment Identity Register (EIR), Signaling Firewall, Session Border Controller (vSBC) and Mobile Edge Gateway enabling operators to understand, monitor, enforce and maintain network security. The security suite fully covers protection of the core mobile network including all communication services enabled by modern CSPs.
About Mavenir:
Mavenir is purpose-built to redefine mobile network economics for Communication Service Providers (CSPs). Our solutions pave the way to 5G with 100% software-based, end-to-end, Cloud Native network solutions. Leveraging industry-leading firsts in VoLTE, VoWiFi, Advanced Messaging (RCS), Multi-ID, vEPC and Cloud RAN, Mavenir accelerates network transformation for more than 250+ CSP customers in over 130 countries, serving over 50% of the world’s subscribers.
We embrace disruptive, innovative technology architectures and business models that drive service agility, flexibility, and velocity. With solutions that propel NFV evolution to achieve web-scale economics, Mavenir offers solutions to CSPs for revenue generation, cost reduction and revenue protection. Mavenir.com
Mavenir, the M logo, and CloudRange are trademarks owned by Mavenir Systems, Inc.
Copyright © 2017 Mavenir Systems, Inc. All Rights Reserved.
1
McKinsey&Company
2
BIC report
3
IHSMarkit
View source version on businesswire.com: http://www.businesswire.com/news/home/20180205005329/en/
Contact:
Media:
Mavenir
Maryvonne Tubb
pr@mavenir.com
or
Loren
Guertin
mavenir@matternow.com
or
Hannah
Locke
mavenir@hotwirePR.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom